A detailed history of Capital International, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital International, Inc. holds 125,221 shares of ALNY stock, worth $30.7 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
125,221
Previous 113,984 9.86%
Holding current value
$30.7 Million
Previous $27.7 Million 24.36%
% of portfolio
0.46%
Previous 0.38%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$233.81 - $287.01 $2.63 Million - $3.23 Million
11,237 Added 9.86%
125,221 $34.4 Million
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $2.95 Million - $5.09 Million
20,608 Added 22.07%
113,984 $27.7 Million
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $973,705 - $1.32 Million
-6,646 Reduced 6.64%
93,376 $14 Million
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $537,354 - $697,626
3,549 Added 3.68%
100,022 $19.1 Million
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $6.6 Million - $8.18 Million
38,626 Added 66.77%
96,473 $17.1 Million
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $1.21 Million - $1.39 Million
6,555 Added 12.78%
57,847 $11 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $745,618 - $961,433
4,082 Added 8.65%
51,292 $10.3 Million
Q4 2022

Feb 14, 2023

BUY
$185.53 - $241.31 $1.51 Million - $1.97 Million
8,148 Added 20.86%
47,210 $11.2 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $429,612 - $719,432
-3,101 Reduced 7.35%
39,062 $7.82 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $2.74 Million - $3.86 Million
22,773 Added 117.45%
42,163 $6.15 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $2.47 Million - $3.37 Million
19,390 New
19,390 $3.17 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.